Drugs and patents in ATC class S01

Last updated: April 25, 2026

What does the ophthalmological market look like by dynamic segments?

ATC S01 is the ophthalmological drug universe: anti-infectives, anti-inflammatory agents, anti-allergy drugs, products for glaucoma, mydriatics, sympathomimetics, tear substitutes and other agents. Competitive intensity and patent life vary by mechanism of action and route of administration.

Market demand drivers (practical read-through for IP strategy)

Demand driver	Typical therapy areas in S01	Patent impact pattern
Aging population and chronic eye disease	Glaucoma, dry eye	Higher repeat development cycles (new formulations, dosing regimens, combination products)
High unmet need in retinal and vision-threatening conditions	Anti-VEGF adjacent areas often sit outside strict S01 in many classifications, but ophthalmic delivery innovations spill into S01	More process and formulation patents; frequent continuation filings
Migration from “drops” to sustained exposure	Glaucoma and inflammation	Formulation and device-linked patents increase; litigation risk grows where dosing changes are incremental but clinically meaningful
Regulatory emphasis on clinical endpoints	Most S01 small molecules and biologics	Stronger linkage between patent scope and endpoints; narrower but higher-value claims in late filing years
Seasonal and acute episodes	Allergic conjunctivitis, infection	Faster filing cadence around narrow indications and dosing schedules

Pricing and access pressure (what it does to IP value)

Chronic, competitive formularies in glaucoma and dry eye pressure prices, increasing reliance on:
- line extensions (new strengths, dosing frequency, preservative systems)
- combinations (add-on MOAs)
- lifecycle management via jurisdiction-specific filing and device-linked claims (e.g., delivery systems, sustained release).
Higher reimbursement scrutiny typically rewards patents that support clear differentiators in:
- dosing frequency
- tolerability (preservative-free systems)
- duration of action
- patient adherence improvements.

Competitive structure and how it maps to patent filings

S01 competition clusters into:

Glaucoma: multi-mechanism pressure (prostanglandin analogs, beta blockers, alpha agonists, Rho kinase inhibitors, carbonic anhydrase inhibitors) with heavy focus on combination therapy and extended exposure.
Anti-infectives and anti-inflammatory: periodic generics pressure in older actives; branded portfolios lean on formulation and dosing innovations.
Allergy: episodic use supports fast follow-on products, with patents often tied to dosing regimen and formulation.

How concentrated is innovation and what claim types dominate?

Across ophthalmologicals, the patent landscape tends to concentrate around a small number of high-value MOAs and delivery approaches, with recurring claim categories:

Dominant IP claim categories in S01

Claim type	Where it shows up	Why it matters for freedom-to-operate
Formulation and preservative system claims	Dry eye, anti-inflammatory regimens, infection control	Often blocks “same drug, different drop” designs
Dose regimen and titration claims	Glaucoma add-ons, post-surgical inflammation	Can delay generic entry where label differs
Device-linked or delivery system claims	Sustained release implants, gels, inserts, contact-adjacent dosing	Can be harder to design around without re-architecting the product
Combination products	Glaucoma (additive MOAs), inflammation/allergy combos	Combination patents can be broader than single-agent patents due to synergistic rationale
Polymorph/crystal form and manufacturing process	Small molecules with solid-state sensitivity	Manufacturing patents can survive after formulation equivalence
New salts/esters/prodrugs	MOA improvement and tolerability	Often narrows literal scope but can preserve exclusivity via regulatory differentiation

Portfolio behavior: “continuations” and jurisdiction strategy

S01 portfolios show a common pattern:

Family diversification by jurisdiction to hedge exam outcomes.
Continuation strategy (where permitted) to keep prosecution active and allow late narrowing.
Local practice variations: claim language and dependent claims differ by office.

Which patent families control exclusivity in S01 and where are the pressure points?

Because ATC S01 spans many distinct drug classes, the “controlling” families differ by sub-portfolio: glaucoma, dry eye/inflammation, allergy, anti-infectives, and surgical ophthalmology. The most actionable pressure points for business are typically:

patents tied to dosing frequency or combination ratios
patents tied to delivery systems (sustained exposure)
patents tied to preservative-free tolerability and ophthalmic viscosity systems
patents tied to manufacturing processes that generic manufacturers struggle to replicate without infringement risk.

Where is the litigation and opposition risk highest?

High risk concentrates where:

generic substitution is commercially attractive (high spend, entrenched prescribing)
label changes allow brand to argue non-equivalence (dosage frequency, indications)
patents are combination or device-linked (design-around requires material changes)
claim scope remains broad in prosecution despite incremental chemistry changes.

Typical S01 risk zones:

Glaucoma combinations and new MOA entries (where first-in-class patents carry follow-on lifecycle families).
Sustained release systems (implant and depot-like delivery) that combine drug chemistry plus device elements.
Dry eye products where formulation and administration characteristics control performance.

What is the practical patent expiry and how should a company plan?

A correct “expiry map” for ATC S01 requires family-level granularity across jurisdictions and each sub-therapy. Without that, the most reliable planning framework for S01 companies is to align product plans to:

active ingredient + immediate formulation family (composition and manufacturing)
label and dose regimen (method-of-use and dosing patents)
delivery format (device-linked claims and sustained release)
combination composition (ratios and co-administration timing)

IP planning checklist for S01 (used by product and FTO teams)

Planning step	Deliverable	Common outcome
Map product to exact label dosing and strength	“Regimen claim coverage”	Identify likely method-of-use risks
Lock delivery architecture	“Device/delivery claim coverage”	Determine whether the design is the workaround
Audit formulation and preservative system	“Composition claim coverage”	Find narrow but blocking formulation patents
Model combination ratios and spacing	“Combination regimen coverage”	Prevent accidental infringement in co-therapy
Track continuation families and office action amendments	“Family claim evolution”	Avoid betting on early claim scope

How should investors read S01 patent metrics?

Investors typically underwrite S01 portfolios using:

family count and family breadth (jurisdiction spread)
claim-type diversity (formulation, regimen, delivery)
regulatory linkage (if a patent supports a label claim, enforceability and commercial leverage rise)
event density: oppositions, reexaminations, patent term adjustments, and litigation outcomes.

A small number of successful portfolios in S01 often outperform broader “shotgun” filing strategies because they:

tie patents directly to differentiators that survive label and clinical use
create multiple enforceable claim pathways (not just one composition patent)
sustain exclusivity through delivery and regimen families rather than only new chemistry.

Actionable views by subcategory (what to do next)

Glaucoma

Prioritize FTO around:
- combinations
- dosing frequency and add-on timing
- delivery systems that extend exposure
Expect heavy lifecycle filing around:
- preservative changes
- concentration/strength adjustments
- solid-state and process improvements that enable re-titration in-device.

Anti-inflammatory and anti-infective ophthalmics

Prioritize:
- formulation claims (viscosity, preservative systems, emulsions)
- dosing regimen claims around post-surgical use
Expect:
- older actives face generics pressure; branded differentiation comes from formulation and regimen.

Allergy and seasonal indications

Prioritize:
- regimen timing and dosing schedules
- formulation stability and administration constraints
Expect:
- faster product turnover; patents often focus on the method and dosing rather than novel actives.

Dry eye (non-infectious chronic)

Prioritize:
- preservative-free and delivery system innovations
- viscosity and tear film interaction claims
Expect:
- high formulation patent density, with incremental changes used for enforcement.

Key Takeaways

S01 innovation clusters in glaucoma and chronic delivery challenges, where exclusivity is sustained through formulation, regimen, and delivery-linked patents, not just new actives.
Patent value maps to label differentiators in dosing frequency, preservative systems, and combination ratios; these claim types drive enforceability and design-around difficulty.
High litigation and opposition risk aligns with products that face imminent generic competition and where patents are combination or delivery system linked.
Investor underwriting should weight claim-type diversity, jurisdiction breadth, and regulatory linkage over raw patent count in S01.
FTO planning in S01 must map the product to exact regimen, delivery architecture, and formulation system; the “workaround” is often in delivery and regimen, not chemistry alone.

FAQs

1) Which S01 area typically carries the highest patent enforcement leverage?

Glaucoma and sustained-exposure delivery systems typically carry the highest leverage because differentiation often links to enforceable regimen and combination or delivery claims.

2) Are formulation patents more important than active ingredient patents in S01?

In many S01 segments, formulation and delivery claims are often as important as, or more important than, active ingredient claims because they block “same drug, different drop” substitutes.

3) What claim types most often slow down generic entry in ophthalmologicals?

Method-of-use (dosing regimen), combination composition/ratio, preservative-free or stability-related formulation, and delivery-device linked claims are the most common blockers.

4) How should a company prioritize jurisdictions for S01 patent families?

Prioritize jurisdictions where (1) the product is expected to be reimbursed and (2) claim construction and prosecution history support enforceability for the specific differentiator used in the label.

5) What investor metrics best predict durability of S01 revenues?

Durability correlates with breadth across claim types (composition, regimen, delivery), regulatory linkage, and observed continuation or claim evolution that maintains enforceable scope.

References

1) WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. World Health Organization. https://www.whocc.no/atc_ddd_index/
2) European Medicines Agency. European Public Assessment Reports (EPARs) and procedural documents for ophthalmic medicines. https://www.ema.europa.eu/
3) FDA. Drug Approval Packages and label information for ophthalmic drugs. https://www.accessdata.fda.gov/

Drugs in ATC Class S01

Subclasses in ATC: S01 - OPHTHALMOLOGICALS

ATC Class S01 (Ophthalmologicals): Market dynamics and patent landscape